Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present the latest data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16. Study results evaluating the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, as well as the investigational sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor, empagliflozin (BI-10773), will be featured among the seven presentations. Linagliptin 5 mg is marketed under the trade name Tradjenta™ (linagliptin) tablets in the U.S. and was approved by the U.S. Food and Drug Administration (FDA) in May 2011 to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

A long-term study evaluating the efficacy and safety of linagliptin in patients with type 2 diabetes was selected by EASD as an oral presentation, taking place on Friday, September 16.

SOURCE Eli Lilly and Company